The furosemide stress test for prediction of worsening acute kidney injury in critically ill patients: A multicenter, prospective, observational study.

Department of Critical Care Medicine, University of Alberta, Edmonton, AB, Canada. Electronic address: rewa@ualberta.ca. Department of Critical Care Medicine, University of Alberta, Edmonton, AB, Canada. Research Facilitation, Analytics (DIMR), Alberta Health Services, Edmonton, AB, Canada. Department of Nephrology, University of Toronto, Toronto, ON, Canada. Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada. Department of Medicine, Medical University of South Carolina, Charleston, SC, USA. Department of Nephrology, University of California San Francisco, San Francisco, CA, USA. Section of Nephrology Department of Medicine, University of Chicago, Chicago, IL, USA. Department of Medicine, University of California - San Diego, San Diego, CA, USA.

Journal of critical care. 2019;:109-114

Abstract

PURPOSE To validate the furosemide stress test (FST) for predicting the progression of acute kidney injury (AKI). MATERIALS AND METHODS We performed a multicenter, prospective, observational study in patients with stage I or II AKI. The FST (1 mg/kg for loop diuretic naïve patients and 1.5 mg/kg in patients previously exposed to loop diuretics) was administered. Subsequent urinary flow rate (UFR) recorded and predictive ability of urinary output was measured by the area under the curve receiver operatic characteristics (AuROC). Primary outcome was progression to Stage III AKI. Secondary outcomes included in-hospital mortality and adverse events. RESULTS We studied 92 critically ill patients. 23 patients progressed to stage III AKI and had significantly lower UFR (p < 0.0001). The UFR during the first 2 h was most predictive of progression to stage III AKI (AuROC = 0.87), with an ideal cut-off of less than 200mls, with a sensitivity of 73.9% and specificity of 90.0%. CONCLUSION In ICU patients without severe CKD with mild AKI, a UFR of less than 200mls in the first 2 h after an FST is predictive of progression to stage III AKI. Future studies should focus on incorporating a FST as part of a clinical decision tool for further management of critically ill patients with AKI.

Methodological quality

Publication Type : Multicenter Study ; Observational Study

Metadata

MeSH terms : Furosemide